Cross-Sector entity
Center for Biologics Evaluation and Research (CBER) is most often covered alongside FDA, which appears in 2 of these 4 stories. regulation accounts for 3 of the 4 tracked stories, while 1 other category carries the remainder. The tracked stories average 6.5 original sources each.
4 verified stories tracked
Last mentioned: Feb 24, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Center for Biologics Evaluation and Research (CBER) is most often covered alongside FDA, which appears in 2 of these 4 stories. regulation accounts for 3 of the 4 tracked stories, while 1 other category carries the remainder. The tracked stories average 6.5 original sources each. This profile follows 4 Cross-Sector stories mentioning Center for Biologics Evaluation and Research (CBER) across the period from February 23, 2026 to February 24, 2026.
Computed from the 4 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Center for Biologics Evaluation and Research (CBER). Shared-story counts are live from our verified record — not editorial picks.
First Approvals
Anticipated first wave of gene therapy approvals under the new streamlined framework.
Expected Finalization
Anticipated period for final guidance after public comment and review.
New System Proposed
FDA formally announces the proposed framework for customized drug approvals.
Expedited Pathway Formalized
FDA announces the formal implementation of quicker paths for gene therapy via surrogate endpoints.
Quicker Path Formalized
Official rollout of the streamlined regulatory framework for gene therapy approvals.
Framework Formalized
FDA officially announces the 'plausible mechanism' framework for ultra-rare disease therapies.
Draft Guidance Issued
FDA releases draft guidance on using surrogate endpoints for gene therapy accelerated approval.
CBER Staffing Surge
FDA completes hiring of 100+ new reviewers dedicated to biologics and gene therapy.
START Pilot Launch
FDA initiates a pilot program for Support for clinical Trials Advancing Rare disease Therapeutics.
START Pilot Launch
FDA launches the Support for clinical Trials Advancing Rare disease Therapeutics (START) pilot program.
START Program
CBER launches the Support for clinical Trials Advancing Rare disease Therapeutics pilot.
START Pilot Program
FDA launches the Support for clinical Trials Advancing Rare disease Therapeutics pilot.
CBER Reorganization
The Office of Tissues and Advanced Therapies is elevated to a 'Super Office' to handle CGT volume.
ASO Guidance
FDA issues initial draft guidance for ASO products for ultra-rare diseases.
Luxturna Approval
FDA approves the first gene therapy for an inherited disease, setting the initial regulatory precedent.
First Gene Therapy Approved
FDA approves Luxturna for a rare form of inherited vision loss.
The FDA has unveiled a proposed regulatory pathway designed to accelerate the approval of customized, patient-specific therapies for ultra-rare diseases. This initiative aims to shift from traditional population-based clinical trials to a data-driven model that supports individualized genomic medicine.
The FDA has officially introduced a streamlined regulatory pathway for gene therapies, allowing for accelerated approval based on 'plausible mechanisms' and biomarkers rather than traditional clinical outcomes. This landmark shift aims to fast-track treatments for ultra-rare diseases where traditional large-scale clinical trials are statistically impossible.
The FDA has launched a streamlined regulatory pathway designed to expedite the development and review of gene therapies, particularly for rare diseases. This initiative marks a significant shift toward using surrogate endpoints and flexible trial designs to bring life-saving treatments to market faster.
The U.S. Food and Drug Administration has established a streamlined regulatory pathway to expedite the development and review of gene therapies. This initiative focuses on leveraging surrogate endpoints and platform technologies to bring life-altering treatments for rare diseases to market faster.
